Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease

Minerva Medica

Volumn 95, Issue 6, 2004, Pages 469-480

  Vestergaard, P ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bone density; Colitis, ulcerative; Crohn disease; Inflammatory bowel diseases; Osteoporosis

Indexed keywords

BONE DENSITY; CLINICAL TRIAL; CROHN DISEASE; ENTERITIS; FEMALE; FRACTURE; HUMAN; MALABSORPTION; MALE; META ANALYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; ULCERATIVE COLITIS;

BONE DENSITY; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FRACTURES, BONE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALABSORPTION SYNDROMES; MALE; OSTEOPOROSIS; RISK FACTORS;

EID: 18444411324     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Vestergaard P. Bone loss associated with gastrointestinal disease: prevalence and pathogenesis. Eur J Gastroenterol Hepatol 2003;15:851-6.
2. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study [see comments]. J Pediatr Gastroenterol Nutr 1997;24:289-95.
3. Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res 2002;17:695-702.
4. Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001;29:498-505.
5. Glickman RM. Inflammatory bowel disease. Ulcerative colitis and Crohn's disease. In: Wilson JD, Braunwald E, Isselbacher KJ, Petersdorf RG, Martin JB, Fauchi AS et al editors. Harrison's principles of internal medicine. New York: McGraw-Hill, Inc., 1991.p.1268-81.
6. Fonager K, Sorensen HT, Olsen J. Change in incidence of Crohn's disease and ulcerative colitis in Denmark. A study based on the National Registry of Patients, 1981-1992. Int J Epidemiol 1997;26:1003-8.
7. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997;40:313-9.
8. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37:192-9.
9. Szulc P, Meunier PJ. Is vitamin K deficiency a risk factor for osteoporosis in Crohn's disease? Lancet 2001;357:1995-6.
10. Hessov I, Mosekilde L, MeLsen F, Fasth S, Hultén L, Lund B et al. Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. Scand J Gastroenterol 1983;19:691-6.
11. Munger RG, Cerhan JR, Chiu BC. Prospective study of dietary protein intake and risk of hip fracture in post-menopausal women. Am J Clin Nutr 1999;69:147-52.
12. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995;10:250-6.
13. Robinson RJ, Iqbal SJ, al-Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther 1998;12:21-5.
14. Bischoff SC, Herrmann A, Goke M, Manns MP, von zur Muhlen A, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997;92:1157-63.
15. Haderslev KV, Jeppesen PB, Sorensen HA, Mortensen PB, Staun M. Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. Gut 2003;52:653-8.
16. Silvennoinen JA, Lehtola JK, Niemela SE. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol 1996;31:367-71.
17. Parfitt AM. Osteomalacia and related disorders. In: Avioli L, Krane SM, editors. Metabolic bone disease and clinically related disorders. San Diego: Academic Press, 2001.p.327-86.
18. Alexeeva L, Burkhardt P, Christiansen C, Cooper C, Delmas P, Johnell O et al. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. Geneva: WHO Technical Report Series 843, 1994;1-129.
19. Khosla S, Melton LJ. Secondary osteoporosis. In: Riggs BL, Melton III LJ, editors. Osteoporosis: etiology, diagnosis, and management. Philadelphia: Lippincott-Raven Publishers, 1995.p.183-204.
20. Shearer MJ. Vitamin K. Lancet 1995;345:229-34.
21. Gundberg CM, Nieman SD, Abrams S, Rosen H. Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. J Clin Endocrinol Metab 1998;83:3258-66.
22. Abitbol V, Roux C, Guillemant S, Valleur P, Hautefeuille P, Dougados M et al. Bone assessment in patients with ileal pouch-anal anastomosis for inflammatory bowel disease. Br J Surg 1997;84:1551-4.
23. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28:410-5.
24. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-8.
25. Compston JE. Detection of osteoporosis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997;9:931-3.
26. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995;37:71-6.
27. Croucher PI, Vedi S, Motley RJ, Garrahan NJ, Stanton MR, Compston JE. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporosis Int 1993;3:236-41.
28. Canalis E. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996;81:3441-6.
29. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000;46:176-81.
30. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993;34:1543-6.
31. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986;104:648-51.
32. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386-90.
33. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996;156:1173-7.
34. Vestergaard P, Mosekilde L. Fracture risk associated with smoking - a meta-analysis. J Intern Med 2003;254:572-83.
35. Blake GM, Wahner HW, Fogelman I. The evaluation of osteoporosis: dual energy X-ray absorptiometry and ultrasound in clinical practice. London: Martin Dunitz; 1999.
36. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
37. Böhning D. Computer-assisted analysis of mixtures and applications: Meta-analysis, disease mapping and others. Boca Raton: Chapman & Hall/CRC; 2000.
38. Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy Monubrun T et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992;37:1396-403.
39. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis [see comments]. Gastroenterology 1994;107:1031-9.
40. Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998;114:902-11.
41. Robinson RJ, Al Azzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998;43:2500-6.
42. Staun M, Tjellesen L, Thale M, Schaadt O, Jarnum S. Bone mineral content in patients with Crohn's disease. A longitudinal study in patients with bowel resections. Scand J Gastroenterol 1997;32:226-32.
43. Teichmann J, Lange U, Stracke H, Doppl W, Klor HU, Federlin K. Rapid spinal trabecular bone loss in female patients with ileitis terminalis Crohn and additional sacroiliac joint inflammation. Rheumatol Int 1997; 17:45-8.
44. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995;108:417-22.
45. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 1998;42:188-94.
46. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998;93:1483-90.
47. Scharia SH, Minne HW, Lempert UG, Leidig G, Hauber M, Raedsch R et al. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). Exp Clin Endocrinol1994;102:44-9.
48. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228-33.
49. Cowan FJ, Warner JT, Dunstan FD, Evans WD, Gregory JW, Jenkins HR. Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child 1997;76: 325-9.
50. Vestergaard P, Emborg C, Støving RK, Hagen C, Mosekilde L, Brixen K. Patients with eating disorders - a high risk group for fractures. Orthop Nursing 2003;22:325-32.
51. Motley RJ, Clements D, Evans WD, Crawley EO, Evans C, Rhodes J et al. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993;23:95-104.
52. Clements D, Motley RJ, Evans WD, Harries AD, Rhodes J, Coles RJ et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992;27:1055-60.
53. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000;133:795-9.
54. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nation-wide follow-up study in 16 416 patients in Denmark. Am J Epidemiol 2002;156:1-10.
55. Loftus EV, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002;123:468-75.
56. van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG. Public health impact of adverse bone effects of oral corticosteroids. J Clin Pharmacol 2001;51:601-7.
57. Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid using patients with inflammatory bowel disease. A pilot study. Aliment Pharmacol Ther 1996;10:777-86.
58. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S et al. Vitamin D, and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637-42.
59. Meyer HE, Smedshaug GB, Kvaavik E, Falch JA, Tverdal A, Pedersen JI. Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Miner Res 2002;17:709-15.
60. Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002;17:1512-26.
61. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R et al. Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Engl J Med 1997;337:382-7.
62. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11.
63. Cortet B, Hachulla E, Barton I, Bonvoisin B, Roux C. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Rev Rhum Engl Ed 1999;66:214-9.
64. Frediani B, Falsetti P, Baldi P, Acciai C, Filippou G, Marcolongo R. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone 2003;33:575-81.
65. Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 1998;83:1128-33.
66. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al. Alendronate for the prevention and treatment of glucorticoid- induced osteoporosis. N Engl J Med 1998;339:292-9.
67. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000;119:639-46.
68. Adachi J, Bensen WG, Bell MJ, Bianchi FA, Cividino AA, Craig GL et al. Salmon calcitonin nasal spray in the prevention of corticosteroid- induced osteoporosis. Br J Rheumatol 1997;36:255-9.
69. Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000;CDO01983.
70. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-35.
71. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.
72. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-33.
73. Clements D, Evans WD, Ryde SS, Rhodes J, Compston JE. Total body calcium in women with inflammatory bowel disease treated with hormone replacement therapy. Eur J Gastroenterol Hepatol 1994;6:21-6.
74. Rossouw JE, Anderson GL, Prentice RL, La Croiz AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
75. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.